Stock listing
BX Swiss:VIR Vir Biotechnology, Inc. Aktie
Swiss listing (BX Swiss) of Vir Biotechnology, Inc. · home listing NASDAQ:VIR
Follow Vir Biotechnology, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:VIR
$8.39 USD -0.76 (-8.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:VIR
- Day range
- $8.34 – $8.92 USDNov 20, 2026
- Volume
- 3.09M sharesNov 20, 2026
- Market cap
- $1.44B USDAt the close on Nov 20, 2026 · price × 171.3M shares outstanding
- 52-week range
- $5.45 – $14.38 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $26.35M USDMedian day 1.85M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VIR · Home | $8.39 USD | -0.76 (-8.3%) | 3,088,951 | $8.807 | $8.915 | $8.34 | $9.15 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VIR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.39 | -0.76 | -8.3% | $8.807 | $8.915 | $8.34 | 3,088,951 | |
| $9.15 | -0.10 | -1.1% | $9.17 | $9.361 | $9.015 | 2,153,818 | |
| $9.25 | -0.33 | -3.4% | $9.53 | $9.75 | $9.03 | 3,480,042 | |
| $9.58 | -0.38 | -3.8% | $9.85 | $10.03 | $9.57 | 6,777,369 | |
| $9.96 | -2.16 | -17.8% | $10.46 | $10.70 | $9.71 | 16,658,905 | |
| $12.12 | -1.01 | -7.7% | $12.90 | $12.96 | $12.02 | 1,945,044 | |
| $13.13 | -0.02 | -0.2% | $13.15 | $13.43 | $12.94 | 1,291,852 | |
| $13.15 | -0.495 | -3.6% | $13.66 | $13.74 | $13.11 | 1,299,670 | |
| $13.65 | +1.435 | +11.8% | $13.18 | $14.38 | $13.11 | 7,120,581 | |
| $12.21 | +1.19 | +10.8% | $11.30 | $12.45 | $11.30 | 1,886,950 | |
| $11.02 | -0.75 | -6.4% | $11.92 | $12.16 | $10.98 | 2,922,141 | |
| $11.77 | +0.55 | +4.9% | $11.68 | $11.81 | $11.17 | 2,425,081 | |
| $11.22 | +0.22 | +2.0% | $11.10 | $11.38 | $11.10 | 1,553,082 | |
| $11.00 | -0.30 | -2.7% | $11.36 | $11.55 | $11.00 | 1,377,376 | |
| $11.30 | -0.45 | -3.8% | $11.63 | $11.84 | $11.18 | 1,267,213 | |
| $11.75 | -0.18 | -1.5% | $11.75 | $12.19 | $11.55 | 1,421,661 | |
| $11.93 | +0.36 | +3.1% | $11.43 | $11.95 | $11.20 | 1,557,240 | |
| $11.57 | +0.53 | +4.8% | $11.00 | $11.63 | $10.86 | 1,972,473 | |
| $11.04 | +0.47 | +4.4% | $10.64 | $11.09 | $10.60 | 1,587,106 | |
| $10.57 | +0.14 | +1.3% | $10.36 | $10.59 | $10.03 | 1,693,540 | |
| $10.43 | -0.14 | -1.3% | $10.51 | $10.75 | $10.18 | 986,582 | |
| $10.57 | -0.17 | -1.6% | $10.80 | $11.02 | $10.55 | 1,136,654 | |
| $10.74 | +0.53 | +5.2% | $10.19 | $10.87 | $10.14 | 1,329,595 | |
| $10.21 | +0.25 | +2.5% | $10.07 | $10.30 | $9.96 | 1,309,172 | |
| $9.96 | -0.51 | -4.9% | $10.49 | $10.49 | $9.91 | 1,735,300 | |
| $10.47 | +0.06 | +0.6% | $10.38 | $10.67 | $10.20 | 1,417,900 | |
| $10.41 | -0.20 | -1.9% | $10.95 | $11.11 | $10.34 | 2,764,900 | |
| $10.61 | -0.69 | -6.1% | $11.21 | $11.25 | $10.60 | 1,783,600 | |
| $11.30 | -0.40 | -3.4% | $11.63 | $11.82 | $11.21 | 1,086,200 | |
| $11.70 | +0.58 | +5.2% | $11.11 | $12.00 | $10.97 | 1,965,100 | |
| $11.12 | -0.40 | -3.5% | $11.52 | $11.56 | $10.73 | 3,071,100 | |
| $11.52 | -0.08 | -0.7% | $11.32 | $11.77 | $11.32 | 3,561,900 | |
| $11.60 | -0.18 | -1.5% | $11.90 | $11.90 | $11.26 | 2,586,700 | |
| $11.78 | +0.61 | +5.5% | $11.17 | $11.87 | $10.92 | 3,147,200 | |
| $11.17 | -0.12 | -1.1% | $11.55 | $11.73 | $10.95 | 2,180,600 | |
| $11.29 | +0.11 | +1.0% | $10.86 | $11.61 | $10.86 | 2,575,800 | |
| $11.18 | +0.53 | +5.0% | $10.70 | $11.26 | $10.54 | 1,737,500 | |
| $10.65 | +0.14 | +1.3% | $10.49 | $10.85 | $10.34 | 1,573,700 | |
| $10.51 | -0.15 | -1.4% | $10.56 | $10.69 | $10.33 | 1,369,900 | |
| $10.66 | -0.06 | -0.6% | $10.82 | $10.82 | $10.48 | 1,126,000 | |
| $10.72 | -0.37 | -3.3% | $11.02 | $11.16 | $10.35 | 2,085,200 | |
| $11.09 | -0.41 | -3.6% | $11.44 | $11.53 | $10.85 | 1,684,800 | |
| $11.50 | +0.62 | +5.7% | $10.99 | $11.72 | $10.89 | 1,852,000 | |
| $10.88 | +0.28 | +2.6% | $10.77 | $10.95 | $10.66 | 1,454,900 | |
| $10.60 | -0.32 | -2.9% | $10.92 | $11.00 | $10.44 | 7,017,200 | |
| $10.92 | +0.40 | +3.8% | $10.87 | $11.21 | $10.68 | 1,791,300 | |
| $10.52 | +0.08 | +0.8% | $10.54 | $10.67 | $10.39 | 2,091,100 | |
| $10.44 | -0.325 | -3.0% | $10.71 | $10.73 | $10.23 | 2,282,200 | |
| $10.77 | +0.145 | +1.4% | $10.73 | $10.94 | $10.64 | 1,841,500 | |
| $10.62 | +0.04 | +0.4% | $10.79 | $10.95 | $10.38 | 2,078,000 | |
| $10.58 | -0.23 | -2.1% | $10.57 | $10.79 | $10.45 | 1,855,300 | |
| $10.81 | -0.37 | -3.3% | $11.04 | $11.38 | $10.74 | 1,945,600 | |
| $11.18 | -0.205 | -1.8% | $11.22 | $11.28 | $10.99 | 1,613,900 | |
| $11.39 | -0.065 | -0.6% | $11.31 | $11.65 | $11.18 | 1,151,300 | |
| $11.45 | -0.05 | -0.4% | $11.54 | $11.62 | $11.07 | 2,565,400 | |
| $11.50 | -0.13 | -1.1% | $11.63 | $11.94 | $11.35 | 3,019,800 | |
| $11.63 | +0.69 | +6.3% | $10.80 | $11.74 | $10.80 | 2,778,100 | |
| $10.94 | +0.11 | +1.0% | $10.77 | $11.17 | $10.65 | 3,046,500 | |
| $10.83 | -0.48 | -4.2% | $11.16 | $11.46 | $10.80 | 1,835,200 | |
| $11.31 | +0.23 | +2.1% | $11.00 | $11.46 | $10.84 | 1,737,300 | |
| $11.08 | +0.37 | +3.5% | $10.60 | $11.12 | $10.30 | 2,248,500 | |
| $10.71 | +0.80 | +8.1% | $10.03 | $11.28 | $9.97 | 2,961,369 | |
| $9.91 | +0.13 | +1.3% | $9.74 | $9.975 | $9.435 | 1,739,718 | |
| $9.78 | +0.57 | +6.2% | $9.31 | $9.86 | $9.305 | 1,756,400 | |
| $9.21 | -0.56 | -5.7% | $9.61 | $9.71 | $9.025 | 1,060,400 |
- Ticker
- BX Swiss:VIR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BX Swiss
- Currency
- CHF
What changed lately
Latest news release · Nov 13, 2026
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Latest earnings call · Nov 4, 2026
Vir Biotechnology (NASDAQ:VIR) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 9, 2026
Technical Presentation (November 2026)
Technical · 23 slides
Latest news
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Nov 12, 2026
Closed $9.96 (-17.8%) on Nov 13, 2026
Vir Biotechnology Announces Proposed Public Offering
Nov 12, 2026
Closed $9.96 (-17.8%) on Nov 13, 2026
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
Nov 8, 2026
Closed $13.65 (+11.8%) on Nov 9, 2026
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
Nov 8, 2026
Closed $13.65 (+11.8%) on Nov 9, 2026
Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call
Nov 5, 2026
Closed $11.02 (-6.4%) on Nov 5, 2026
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Nov 4, 2026
Closed $11.02 (-6.4%) on Nov 5, 2026
Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
Nov 2, 2026
Closed $11.22 (+2.0%) on Nov 3, 2026
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
Oct 28, 2026
Closed $11.93 (+3.1%) on Oct 28, 2026
Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
Oct 21, 2026
Closed $10.43 (-1.3%) on Oct 22, 2026
Vir Biotechnology, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 37 in the last 12 months · 246 in all · newest Nov 13, 2026 · oldest 2019
- Calls
- 14 calls with a replay · 14 with a transcript · latest Nov 4, 2026
- Decks
- 32 decks · latest Nov 9, 2026
Where Vir Biotechnology, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VIR · Home listing | NASDAQ | United States | USD |
| BMV:VIR | BMV | Mexico | MXN |
| BIVA:VIR | BIVA | Mexico | MXN |
| BX Swiss:VIR · This page | BX Swiss | Switzerland | CHF |
| BOATS:VIR | BOATS | United States | USD |
Valuation
EV/sales 3.5× against a median of 52.7×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.07B USD
- P/E
- Loss
- EV/sales
- 3.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.6×
- Gross margin
- 97.2%
- Operating margin
- −69.8%
- Net margin
- −61.0%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.82
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| Alvotech · NASDAQ:ALVO | US$1.47B | US$2.78B | n/a | 5.7× | 31.4× | n/a | −36.5% | n/a | 0.90 |
| ABL Bio, Inc. · KRX:298380 | US$1.47B | US$1.34B | n/a | 52.7× | n/a | 11.5× | −229.4% | 0.0× | n/a |
| Mesoblast Limited · ASX:MSB | US$1.46B | US$1.42B | n/a | 82.6× | n/a | 2.4× | −593.9% | 0.2× | n/a |
| PELL Bio-Med Technology Co Ltd · TWSE:6949 | US$1.46B | US$1.40B | n/a | 1,591× | n/a | 18.7× | n/a | 0.1× | n/a |
| Damora Therapeutics, Inc. · NASDAQ:DMRA | US$1.44B | US$910.0M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 0.88 |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.39B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| LigaChem Biosciences Inc. · KRX:141080 | US$1.42B | US$1.14B | n/a | 15.5× | n/a | 4.8× | −180.9% | 0.0× | n/a |
| ADARx Pharmaceuticals, Inc. · NASDAQ:ADRX | US$1.42B | US$521.8M | n/a | 77.6× | n/a | 2.5× | n/a | 0.0× | n/a |
| Median of the others | US$1.44B | US$1.37B | 52.7× | 31.4× | 2.9× | −180.9% | 0.0× | 1.09 |
Forecasts
5 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 23.13 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.01 · 8 analysts
- Revenue, year to Dec 2026
- 327.2M · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Marianne De Backer | PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR |
| Aziz Sawaf | EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICer |
| Vanina de Verneuil | Executive Vice President General Counsel and Corporate Secretary |
| Carolyn Wang | SENIOR VICE PRESIDENT CORPORATE COMMUNICATIONS |
| InvestorsNeera Ravindran | MDHead of Investor Relations & Strategic |
| Kiki Patel | PharmDHead of Investor Relations |
| David Liu | EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER |
| Jeff Calcagno | Executive Vice President and Chief Business Officer |
| Jennifer Eileen Towne | Executive Vice President and Chief Scientific Officer |
| Maninder Hora | EXECUTIVE VICE PRESIDENT AND CHIEF TECHNICAL OPERATIONS OFFICER |
| Toby Medaris | EXECUTIVE VICE PRESIDENT AND CHIEF HUMAN RESOURCES OFFICER |
| Brent Sabatini | Interim Principal Financial Officer |
Board
| Director | Role |
|---|---|
| Jeffrey S. Hatfield | Chair of the Board |
| Elliott Sigal | Director |
| Janet Napolitano | Director |
| Marianne De Backer | PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR |
| Norbert Bischofberger | Director |
| Ramy Farid | Director |
| Robert More | Director |
| Suzanne L. Topalian | Director |
| Timothy Coughlin | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Vir Biotechnology (NASDAQ:VIR) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q1 2026 Earnings Call | Wed, May 06, 2026 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q4 2025 Earnings Call | Mon, Feb 23, 2026 · 5:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q1 2025 Earnings Call | Wed, May 07, 2025 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q3 2024 Earnings Call | Thu, Oct 31, 2024 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 4:30 PM ET | Replay |
All 14 calls
| Call | When | Status |
|---|---|---|
| Vir Biotechnology (NASDAQ:VIR) Q1 2024 Earnings Call | Thu, May 02, 2024 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q4 2023 Earnings Call | Thu, Feb 22, 2024 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q3 2023 Earnings Call | Thu, Nov 02, 2023 · 4:30 PM ET | Replay |
| Vir Biotechnology (NASDAQ:VIR) Q2 2023 Earnings Call | Thu, Aug 03, 2023 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −6.4% |
| Q2 2026 | Aug 5, 2026 · After close | −3.8% |
| Q1 2026 | May 6, 2026 · After close | −9.9% |
| Q4 2025 | Feb 23, 2026 | +25.5% |
| Q3 2025 | Nov 5, 2025 · After close | −5.2% |
| Q2 2025 | Aug 6, 2025 · After close | −14.4% |
| Q1 2025 | May 7, 2025 · After close | −3.6% |
| Q4 2024 | Feb 20, 2025 · After close | −2.4% |
| Q3 2024 | Oct 31, 2024 · After close | +23.6% |
| Q2 2024 | Aug 1, 2024 · After close | −5.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | +13.2% |
| Q4 2023 | Feb 22, 2024 · After close | +11.9% |
| Q3 2023 | Nov 2, 2023 · After close | +7.0% |
| Q2 2023 | Aug 3, 2023 · After close | −2.5% |
| Q1 2023 | May 4, 2023 · After close | −3.9% |
| Q4 2022 | Feb 23, 2023 · After close | −10.9% |
| Q3 2022 | Nov 3, 2022 · After close | +17.7% |
| Q2 2022 | Aug 9, 2022 · After close | +6.3% |
| Q1 2022 | May 5, 2022 · After close | +3.5% |
| Q4 2021 | Feb 24, 2022 · After close | −1.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2026) | Technical | 23 slides | Nov 9, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 61 slides | Nov 4, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 62 slides | Aug 5, 2026 |
| Technical Presentation (May 2026) | Technical | 10 slides | May 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 61 slides | May 6, 2026 |
| FY2025 Earnings Presentation | Earnings | 35 slides | Feb 23, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 56 slides | Feb 23, 2026 |
| J.P. Morgan 2026 Healthcare Conference | Conference | 26 slides | Jan 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 45 slides | Nov 5, 2025 |
| Investor Presentation (November 2025) | Investor deck | 47 slides | November 2025 |
All 32 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$150M · US$10 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), Morgan Stanley (co-lead), Evercore ISI (co-lead), Raymond James | Nov 13, 2026 |
| Strategic investment of equity Announced: US$25M Buyers: Gilead ($25 million equity investment at a 30% premium) | Oct 14, 2026 |
| Strategic investment of shares Closed: US$75M raised · US$10.36 a share Buyers: Astellas ($75 million equity investment at a price of $10.36 per share) | Apr 16, 2026 |
| Public offering of common stock Terms changed: US$150M · US$8.5 a share · Goldman Sachs & Co. LLC +3 Dealers: Goldman Sachs & Co. LLC (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), Barclays (co-lead) | Feb 26, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$20.00 a share on Oct 10, 2019.
- Price
- US$20.00 a share
- Shares offered
- 7,142,858 shares of common stock
- Offering size
- US$142.9 million
- Underwriters' option
- Up to 1,071,428 more shares
- Underwriters
- Goldman Sachs & Co. LLC, J.P. Morgan, Cowen, Barclays · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 27, 2019 |
| Filed publicly | Sep 3, 2019 |
| Amended once | Sep 30, 2019 |
| Shares registered with an exchange | Oct 9, 2019 |
| Declared effective by the SEC | Oct 10, 2019 |
| Final prospectus, with the price | Oct 11, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 11, 2019 |
| EFFECT · Notice that a registration is effective | Oct 10, 2019 |
| CERT · Exchange's certificate of listing | Oct 10, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 9, 2019 |
| CORRESP · Letter to the SEC | Oct 8, 2019 |
| CORRESP · Letter to the SEC | Oct 8, 2019 |
| CORRESP · Letter to the SEC | Sep 30, 2019 |
| S-1/A · Registration statement, amended | Sep 30, 2019 |
| CORRESP · Letter to the SEC | Sep 17, 2019 |
| UPLOAD · Letter from the SEC | Sep 10, 2019 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 3, 2019 |
| S-1 · Registration statement | Sep 3, 2019 |
| UPLOAD · Letter from the SEC | Aug 26, 2019 |
| DRSLTR · Letter to the SEC with a draft | Aug 7, 2019 |
| DRS/A · Draft registration statement, amended | Aug 7, 2019 |
| UPLOAD · Letter from the SEC | Jul 25, 2019 |
| DRS · Draft registration statement | Jun 27, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 11, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68.6M | 74.2M | 86.2M | 1.62B | 1.10B | 76.4M | 8.09M | 10.7M | 2.71M |
| Cost of revenue | 26.0K | 845.0K | 2.77M | 146.3M | 65.9M | 0 | 0 | 100.2M | 62.5M |
| Gross profit | 56.9M | 58.8M | 64.0M | 1.45B | 1.02B | 76.4M | 711.0K | -99.4M | -62.4M |
| Research and development | 456.0M | 506.5M | 579.7M | 474.6M | 448.0M | 302.4M | 148.5M | 100.2M | 62.5M |
| Selling, general and administrative | 92.1M | 119.0M | 174.4M | 161.8M | 160.8M | 70.9M | 37.6M | 29.1M | 21.7M |
| Operating income | -479.3M | -587.2M | -684.3M | 833.1M | 420.8M | -297.0M | -178.0M | -118.7M | -81.5M |
| Depreciation and amortization | 11.7M | 14.6M | 19.5M | 6.78M | 5.28M | 4.40M | 3.29M | 1.62M | 255.0K |
| EBITDA | -467.6M | -572.6M | -664.9M | 839.9M | 426.0M | -292.6M | -174.7M | -117.1M | -81.2M |
| Interest expense | 183.1M | 272.9M | 3.81M | 7.97M | 0 | 0 | |||
| Income before tax | -437.8M | -523.1M | -628.2M | 754.3M | 549.8M | -298.6M | -174.5M | -116.4M | -80.8M |
| Income tax | 217.0K | -1.15M | -13.1M | 238.4M | 21.2M | 54.0K | 154.0K | -480.0K | -10.9M |
| Net income | -438.0M | -522.0M | -615.1M | 515.8M | 528.6M | -298.7M | -174.7M | -115.9M | -69.9M |
| Earnings per share, basic | -3.16 | -3.83 | -4.59 | 3.89 | 4.07 | -2.51 | -5.76 | -15.12 | -32.45 |
| Earnings per share, diluted | -3.16 | -3.83 | -4.59 | 3.83 | 3.96 | -2.51 | -5.76 | -15.12 | -32.45 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 232.2M | 222.9M | 241.6M | 848.6M | 347.8M | 436.6M | 109.3M | 47.6M | 187.9M |
| Short-term investments | 228.8M | 678.1M | 1.27B | 1.52B | 217.2M | 300.3M | 274.1M | 50.8M | 0 |
| Receivables | 3.60M | 5.10M | 11.6M | 0 | 773.1M | 0 | |||
| Inventory | 8.59M | 0 | 0 | ||||||
| Current assets | 514.1M | 1.04B | 1.59B | 2.52B | 1.56B | 772.4M | 403.0M | 117.8M | 192.3M |
| Property, plant and equipment | 55.6M | 63.2M | 96.0M | 105.6M | 42.8M | 17.9M | 16.3M | 12.3M | 5.14M |
| Goodwill | 16.9M | 16.9M | 16.9M | 16.9M | 16.9M | 16.9M | 16.9M | 16.9M | 16.9M |
| Total assets | 1.00B | 1.40B | 1.92B | 2.80B | 1.95B | 918.8M | 512.1M | 191.6M | 251.6M |
| Accounts payable | 9.80M | 5.08M | 6.33M | 6.42M | 6.52M | 5.08M | 5.88M | 6.47M | 4.90M |
| Current liabilities | 92.8M | 119.7M | 175.4M | 511.0M | 341.2M | 99.1M | 59.2M | 39.9M | 12.4M |
| Long-term debt | 0 | 0 | |||||||
| Total debt | 186.9M | 97.9M | 124.5M | 128.0M | 137.5M | 70.2M | 1.14M | 10.1M | |
| Total liabilities | 237.5M | 248.4M | 328.8M | 724.1M | 522.4M | 201.9M | 88.1M | 61.6M | 320.5M |
| Shareholders' equity | 765.3M | 1.15B | 1.59B | 2.08B | 1.43B | 716.9M | 423.9M | -179.2M | -68.9M |
| Shares outstanding | 139.5M | 137.0M | 134.8M | 133.2M | 131.2M | 127.4M | 107.6M | 8.86M | 127.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -391.8M | -446.4M | -778.8M | 1.66B | -47.6M | -190.9M | -129.6M | -94.1M | -66.4M |
| Capital spending | -4.83M | -7.30M | -21.6M | -68.0M | -21.8M | -6.55M | -8.94M | -8.19M | -2.74M |
| Free cash flow | -396.6M | -453.7M | -800.4M | 1.60B | -69.4M | -197.5M | -138.6M | -102.3M | -69.1M |
| Cash from investing | 310.4M | 499.4M | 164.6M | -1.19B | -140.8M | -9.86M | -256.2M | -60.4M | -30.0M |
| Cash from financing | 3.79M | 4.39M | 7.48M | 34.8M | 100.3M | 529.5M | 449.2M | 25.0M | 271.2M |
| Dividends paid | 0 | 0 | |||||||
| Share buybacks | 3.22M | 15.4M | 327.3M | -3.00K | 14.8M | 0 | |||
| Change in cash | -77.6M | 57.4M | -606.7M | 504.6M | -88.1M | 328.7M | 63.5M | -129.6M | 174.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Nov 16, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 13, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Nov 13, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Nov 12, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Nov 12, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 14, 2026 | Financing | SEC |
| 8-K · Current report | Oct 8, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Sep 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 24, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 8-K · Current report | May 28, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 30, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 16, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 10, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 23, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 4, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 3, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 8-K · Current report | Feb 26, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 26, 2026 | Offer document | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Feb 24, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 23, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 23, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 23, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 14, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 8-K · Current report | Dec 16, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 2, 2025 | Other filings | SEC |
| 8-K · Current report | May 29, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 9, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 28, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 17, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2025 | Annual report | SEC |
| 144 · Notice of proposed sale | Feb 26, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 13, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 30, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 8, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
This page holds 200 of 811 filings. Open Filings
Cap table
Built by 6ix from Vir Biotechnology, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 171,270,773
- Fully diluted
- 171,270,773
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 171,270,773 | Oct 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 28, 2026 | 171,270,773 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Nelsen Other companies: City Therapeutics, Inc. (Board Director · Since at least Oct 19, 2026); Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Mar 31, 2021 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Apr 13, 2021 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 2, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 8, 2017 · Past); Bellerophon Therapeutics Inc (Director · Feb 12, 2015 – Feb 13, 2015 · Past); Juno Therapeutics Inc (Director · Dec 18, 2014 – Mar 5, 2018 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Nov 9, 2015 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Oct 4, 2013 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Mar 3, 2017 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Aug 14, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Jun 7, 2012 · Past); Adolor Corp (Director · May 18, 2006 – May 17, 2007 · Past) | Director · Oct 10, 2019 – May 30, 2024 · Past |
| Kristina Burow Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Jan 30, 2025); Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Scholar Rock Holding Corporation (Director · Since at least May 23, 2018); Metacrine Inc (Director · Sep 15, 2020 – May 24, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Jun 6, 2023 · Past); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Receptos Inc (Director · Aug 25, 2015 – Aug 25, 2015 · Past) | Director · Oct 10, 2019 – May 21, 2020 · Past |
| Robert J Perez Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Immunocore Holdings plc (Director · Jan 2, 2024 – Jan 2, 2024 · Past); Third Harmonic Bio Inc. (Director · Sep 14, 2022 – Mar 6, 2023 · Past); Cogent Biosciences, Inc. (Director · Mar 28, 2018 – Jun 14, 2019 · Past); Spark Therapeutics Inc (Director · Jan 3, 2018 – Dec 17, 2019 · Past); Larimar Therapeutics, Inc. (Director · Sep 24, 2015 – Jun 26, 2019 · Past); Decoy Therapeutics Inc. (Director · Sep 2, 2015 – Jul 26, 2017 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 22, 2017 · Past); AMAG Pharmaceuticals Inc (Director · Jan 26, 2009 – May 16, 2019 · Past); Cubist Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 3, 2006 – Jan 21, 2015 · Past) | Director · Oct 10, 2019 – May 22, 2023 · Past |
| Vicki Sato Other companies: Allogene Therapeutics, Inc. (Director · Since at least Jul 30, 2021); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jan 2, 2025 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 11, 2019 · Past); BorgWarner Inc. (Director · Feb 12, 2014 – Apr 29, 2020 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2007 – Jun 2, 2010 · Past); Bristol-Myers Squibb Company (Director · Jul 11, 2006 – Feb 1, 2021 · Past); Revvity, Inc. (Director · May 2, 2006 – Feb 9, 2017 · Past) | Director · Since at least Oct 10, 2019 |
| Saira Ramasastry Other companies: Sensei Biotherapeutics, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least Jun 15, 2026); Mirum Pharmaceuticals, Inc. (Director · Since at least Jun 2, 2022); Day One Biopharmaceuticals Inc (Director · Since at least May 26, 2021); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Repros Therapeutics (Director · Mar 25, 2013 – Jan 29, 2018 · Past); Filana Therapeutics, Inc. (Director · Feb 11, 2013 – Dec 13, 2019 · Past); Sangamo Therapeutics, Inc. (Director · Jun 21, 2012 – Feb 25, 2022 · Past) | Director · Since at least Oct 10, 2019 |
| Dipchand Nishar Other companies: Seer, Inc. (Director · Since at least Feb 13, 2021); Senti Biosciences Holdings, Inc. (Director · May 25, 2021 – May 25, 2021 · Past); Relay Therapeutics, Inc. (Director · Jul 15, 2020 – Jul 15, 2020 · Past); Guardant Health, Inc. (Director · Oct 3, 2018 – May 18, 2020 · Past); TripAdvisor, Inc. (Director · Sep 5, 2013 – Jun 21, 2019 · Past); LinkedIn Corp (SVP, Products, User Experience · May 18, 2011 – Sep 2, 2014 · Past) | Director · Oct 10, 2019 – May 21, 2021 · Past |
| Jeffrey S. Hatfield Other companies: Larimar Therapeutics, Inc. (Chief Executive Officer, Director · Oct 9, 2017 – Jan 22, 2019 · Past); Viridian Therapeutics, Inc. (Director · Aug 10, 2017 – Feb 4, 2021 · Past); aTyr Pharma, Inc. (Director · Apr 3, 2017 – May 6, 2020 · Past); InVivo Therapeutics Holdings Corp (Director · Nov 1, 2016 – Jan 19, 2018 · Past); Vitae Pharmaceuticals Inc (Chief Executive Officer, Director · Sep 24, 2014 – Oct 24, 2016 · Past); Ambit Biosciences Corp (Director · Jun 2, 2014 – Nov 10, 2014 · Past) | Chair of the Board · Since at least Dec 9, 2020 |
| Michael E Kamarck Other companies: Passage Bio, Inc. (Director · Jul 2, 2022 – May 25, 2023 · Past); Vaxcyte, Inc. (Director · Oct 27, 2021 – Jun 13, 2023 · Past); Trillium Therapeutics Inc (Director · Jan 1, 2021 – Nov 17, 2021 · Past); Unilife Corp (Director · Jul 28, 2016 – Jul 28, 2016 · Past); Omni Bio Pharmaceutical Inc (Director · Jan 31, 2013 – Jan 31, 2013 · Past) | Chief Technology Officer · Oct 10, 2019 – Oct 10, 2019 · Past |
| Timothy P. Coughlin Other companies: ADC Therapeutics SA (Director · Since at least Jun 3, 2025); aTyr Pharma, Inc. (Chairman · Since at least Apr 7, 2017); Travere Therapeutics, Inc. (Director · Since at least Mar 31, 2015); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Jun 7, 2024 · Past); Neurocrine Biosciences, Inc. (Chief Financial Officer · Sep 18, 2006 – Feb 6, 2017 · Past) | Director · Since Jun 9, 2026 |
| George Scangos Other companies: Voyager Therapeutics, Inc. (Director · Since at least May 9, 2023); Agilent Technologies, Inc. (Director · Since at least Mar 16, 2017); Exelixis, Inc. (Director · May 26, 2016 – May 18, 2020 · Past); Biogen Inc. (Chief Executive Officer, Director · Apr 1, 2016 – Jul 21, 2016 · Past) | Director · Oct 10, 2019 – Feb 24, 2025 · Past |
All 43 people
| Person | Seat |
|---|---|
| Charles Elliott Sigal Other companies: Alnylam Pharmaceuticals, Inc. (Director · Since at least Aug 22, 2022); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Jul 3, 2023 · Past) | Director · Since at least Jul 10, 2020 |
| Mark Eisner Other companies: Jade Biosciences, Inc. (Director · Since at least Jun 25, 2026); Zura Bio Limited (Director · Since at least Feb 21, 2026); Kyntra Bio, Inc. (EVP, Chief Medical Officer · Dec 1, 2020 – Sep 6, 2023 · Past) | EVP and Chief Medical Officer · Since at least Jun 3, 2024 |
| Norbert Bischofberger Other companies: Kronos Bio Inc (Director · Since at least Oct 8, 2020); Morphic Holding Inc (Director · Jun 26, 2019 – Aug 16, 2024 · Past); Gilead Sciences, Inc. (EVP, R&D and CSO · Jan 25, 2006 – Feb 15, 2018 · Past) | Director · Since at least May 29, 2024 |
| Phillip A Sharp Other companies: Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 1, 2022 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2006 – Jan 23, 2025 · Past); Biogen Inc. (Director · Jan 9, 2006 – Jun 3, 2009 · Past) | Director · Oct 10, 2019 – May 22, 2023 · Past |
| Sung Lee Other companies: Tango Therapeutics, Inc. (Executive Vice President and Chief Financial Officer, Cytokinetics · Since at least Jan 2, 2026); Cytokinetics, Incorporated (EVP, Chief Financial Officer · Since at least Apr 26, 2024); Sangamo Therapeutics, Inc. (EVP, Chief Financial Officer · Oct 31, 2019 – Nov 25, 2020 · Past) | EVP & Chief Financial Officer · Mar 27, 2023 – Mar 27, 2024 · Past |
| Janet Napolitano Other companies: Fortinet, Inc. (Director · Since at least Nov 7, 2024); Zoom Communications, Inc. (Director · Since at least Nov 2, 2020) | Director · Since at least Aug 28, 2020 |
| Jason V. O'Byrne Other companies: Olema Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Aug 11, 2026); Caribou Biosciences, Inc. (Chief Financial Officer · Jul 22, 2021 – Feb 20, 2024 · Past) | EVP & Chief Financial Officer · Since at least Oct 2, 2024 |
| Marianne De Backer Other companies: Kronos Bio Inc (Director · Jan 25, 2021 – Jun 22, 2023 · Past); Arrowhead Pharmaceuticals, Inc. (Director · Dec 12, 2019 – Jan 10, 2023 · Past) | PRESIDENT, CHIEF EXECUTIVE OFFICER AND DIRECTOR · Since at least Apr 3, 2023 |
| Ramy Farid Other companies: Schrodinger, Inc. (President and CEO, Board Member · Since at least Feb 5, 2020); Structure Therapeutics, Inc. (Director · Feb 2, 2023 – Feb 7, 2023 · Past) | Director · Since at least May 29, 2024 |
| Robert More Other companies: Tyra Biosciences, Inc. (Board Member · Since at least Sep 14, 2021); Glaukos Corporation (Director · Jun 24, 2015 – Jun 30, 2015 · Past) | Director · Since at least Oct 10, 2019 |
| Aziz Sawaf Other companies: Theravance Biopharma, Inc. (SVP & CHIEF FINANCIAL OFFICER · Since at least Jan 1, 2023) | EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICer · Since at least Oct 1, 2026 |
| Elliott Sigal Other companies: Alnylam Pharmaceuticals, Inc. (Director · Since at least Nov 4, 2026) | Director · Since at least Nov 5, 2026 |
| Howard Horn Other companies: Ultragenyx Pharmaceutical Inc. (Chief Financial Officer · Since at least Oct 9, 2023) | CFO · Oct 10, 2019 – Feb 23, 2023 · Past |
| Johanna Friedl-Naderer Other companies: Dyne Therapeutics, Inc. (Chief Commercial Officer · Since at least Sep 3, 2024) | EVP & Chief Operating Officer · Mar 2, 2022 – Mar 3, 2023 · Past |
| Ann M Hanly | EVP & Chief Technology Officer · Mar 29, 2021 – Feb 24, 2025 · Past |
| Arran Attridge | Senior Vice President, Corporate Communications · Mar 13, 2025 – Nov 4, 2026 · Past |
| Brent Sabatini | Interim Principal Financial Officer · Since at least Oct 1, 2024 |
| Carolyn Wang | SENIOR VICE PRESIDENT CORPORATE COMMUNICATIONS · Since at least Nov 5, 2026 |
| David Liu | EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER · Since at least Oct 7, 2026 |
| Herbert Virgin | EVP, Research & CSO · Oct 10, 2019 – Aug 9, 2022 · Past |
| InvestorsNeera Ravindran | MDHead of Investor Relations & Strategic · Since at least Feb 23, 2026 |
| Jay Parrish | Chief Business Officer · Oct 10, 2019 – Apr 1, 2021 · Past |
| Jeff Calcagno | Executive Vice President and Chief Business Officer · Since at least Nov 4, 2026 |
| Jennifer Eileen Towne | Executive Vice President and Chief Scientific Officer · Since at least Nov 5, 2026 |
| Kiki Patel | PharmDHead of Investor Relations · Since at least Nov 2, 2026 |
| Klaus Frueh | Director · Oct 10, 2019 – Oct 16, 2019 · Past |
| Maninder Hora | EXECUTIVE VICE PRESIDENT AND CHIEF TECHNICAL OPERATIONS OFFICER · Since at least Feb 26, 2025 |
| Phillip Pang | EVP & Chief Medical Officer · Oct 10, 2019 – Feb 22, 2024 · Past |
| Richard Lepke | Senior Director, Investor Relations · Oct 9, 2025 – Nov 4, 2026 · Past |
| Steven J Rice | Chief Administrative Officer · Jul 30, 2020 – Jun 1, 2023 · Past |
| Suzanne Topalian | Director · Since at least Oct 27, 2026 |
| Toby Medaris | EXECUTIVE VICE PRESIDENT AND CHIEF HUMAN RESOURCES OFFICER · Since at least Nov 4, 2026 |
| Vanina de Verneuil | Executive Vice President General Counsel and Corporate Secretary · Since at least Oct 1, 2024 |
Log in to ask 6ix AI your own questions about Vir Biotechnology, Inc.